Cocaine and Opioid Use in Pregnancy Linked to Worse Newborn Outcomes Than Cannabis Alone

Pregnant women using cocaine and/or opioids had nearly 4 times higher odds of adverse newborn outcomes compared to those using only cannabis.

Kandhasamy, Sreemanjari et al.·BMC pregnancy and childbirth·2025·Moderate Evidenceretrospective cohort
RTHC-06789Retrospective cohortModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
retrospective cohort
Evidence
Moderate Evidence
Sample
N=80

What This Study Found

Among 177 pregnant women followed for addiction, those using cocaine and/or opioids (with or without cannabis) had 3.88 times higher odds of adverse neonatal outcomes compared to cannabis-only users. Surprisingly, cocaine/opioid exposure was associated with lower odds of adverse obstetrical outcomes (OR=0.39). 81.2% of the exposed group used opioids and 39.9% used cocaine.

Key Numbers

177 pregnant women: 80 exposed (cocaine/opioids), 97 reference (cannabis-only). Adverse neonatal outcomes: ORconditional=3.88 (95% CI: 1.23-12.23). Adverse obstetrical outcomes: ORconditional=0.39 (95% CI: 0.17-0.88). 81.2% opioids, 39.9% cocaine in exposed group.

How They Did This

Observational study at the Addi-Vie perinatal consultation center, CHUV Lausanne, Switzerland. 80 women using cocaine/opioids (with or without cannabis) compared to 97 cannabis-only users. Inverse probability treatment weighting used for adjusted analysis.

Why This Research Matters

Using cannabis-only users as the reference group (instead of drug-free controls) provides a more clinically relevant comparison for addiction medicine, better controlling for confounders associated with polysubstance use.

The Bigger Picture

By using cannabis-only as the reference, this study implicitly positions cannabis as a less harmful substance during pregnancy compared to cocaine and opioids, though it does not assess cannabis versus no substance use.

What This Study Doesn't Tell Us

Small sample from a single center. Cannabis-only reference group is not the same as a drug-free control. Cannot distinguish effects of individual substances within the exposed group. The unexpected protective obstetrical finding may reflect more intensive monitoring of higher-risk patients.

Questions This Raises

  • ?Why were obstetrical outcomes better in the cocaine/opioid group?
  • ?Would outcomes differ if the reference group were substance-free women?

Trust & Context

Key Stat:
3.88x higher odds of adverse neonatal outcomes with cocaine/opioids versus cannabis-only exposure in pregnancy
Evidence Grade:
Novel reference group approach with appropriate weighting, but small sample, single center, and inability to isolate individual substance effects limit conclusions.
Study Age:
2025 publication.
Original Title:
Risk of adverse obstetrical and neonatal outcomes in women consuming recreational drugs during pregnancy.
Published In:
BMC pregnancy and childbirth, 25(1), 456 (2025)
Database ID:
RTHC-06789

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkTHC

Cite This Study

RTHC-06789·https://rethinkthc.com/research/RTHC-06789

APA

Kandhasamy, Sreemanjari; Lepigeon, Karine; Baggio, Stéphanie; Céline, Roulet; Ceulemans, Michael; Winterfeld, Ursula; Jenkinson, Stephen P; Francini, Katyuska; Maisonneuve, Emeline; Panchaud, Alice. (2025). Risk of adverse obstetrical and neonatal outcomes in women consuming recreational drugs during pregnancy.. BMC pregnancy and childbirth, 25(1), 456. https://doi.org/10.1186/s12884-024-07062-1

MLA

Kandhasamy, Sreemanjari, et al. "Risk of adverse obstetrical and neonatal outcomes in women consuming recreational drugs during pregnancy.." BMC pregnancy and childbirth, 2025. https://doi.org/10.1186/s12884-024-07062-1

RethinkTHC

RethinkTHC Research Database. "Risk of adverse obstetrical and neonatal outcomes in women c..." RTHC-06789. Retrieved from https://rethinkthc.com/research/kandhasamy-2025-risk-of-adverse-obstetrical

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.